1. Home
  2. SLN vs MEI Comparison

SLN vs MEI Comparison

Compare SLN & MEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • MEI
  • Stock Information
  • Founded
  • SLN 1994
  • MEI 1946
  • Country
  • SLN United Kingdom
  • MEI United States
  • Employees
  • SLN N/A
  • MEI N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • MEI Electrical Products
  • Sector
  • SLN Health Care
  • MEI Technology
  • Exchange
  • SLN Nasdaq
  • MEI Nasdaq
  • Market Cap
  • SLN 268.8M
  • MEI 256.0M
  • IPO Year
  • SLN N/A
  • MEI N/A
  • Fundamental
  • Price
  • SLN $6.59
  • MEI $7.35
  • Analyst Decision
  • SLN Buy
  • MEI Buy
  • Analyst Count
  • SLN 6
  • MEI 2
  • Target Price
  • SLN $39.67
  • MEI $11.25
  • AVG Volume (30 Days)
  • SLN 115.5K
  • MEI 336.8K
  • Earning Date
  • SLN 11-13-2025
  • MEI 12-04-2025
  • Dividend Yield
  • SLN N/A
  • MEI 3.81%
  • EPS Growth
  • SLN N/A
  • MEI N/A
  • EPS
  • SLN N/A
  • MEI N/A
  • Revenue
  • SLN $27,169,000.00
  • MEI $1,030,100,000.00
  • Revenue This Year
  • SLN N/A
  • MEI N/A
  • Revenue Next Year
  • SLN N/A
  • MEI $3.55
  • P/E Ratio
  • SLN N/A
  • MEI N/A
  • Revenue Growth
  • SLN 22.28
  • MEI N/A
  • 52 Week Low
  • SLN $1.97
  • MEI $5.08
  • 52 Week High
  • SLN $19.36
  • MEI $17.45
  • Technical
  • Relative Strength Index (RSI)
  • SLN 69.56
  • MEI 46.11
  • Support Level
  • SLN $5.00
  • MEI $6.87
  • Resistance Level
  • SLN $5.83
  • MEI $7.50
  • Average True Range (ATR)
  • SLN 0.41
  • MEI 0.33
  • MACD
  • SLN 0.16
  • MEI -0.06
  • Stochastic Oscillator
  • SLN 93.42
  • MEI 31.67

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About MEI Methode Electronics Inc.

Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.

Share on Social Networks: